Reverse Payments: From Cash to Quantity Restrictions and Other Possibilities
Today, staff of the Bureau of Competition published four reports covering fiscal years 2018, 2019, 2020, and 2021 on the types and terms of the pharmaceutical patent settlement agreements filed with the FTC under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (“MMA”). The MMA requires brand drug and generic manufacturers (and since October 2018, biologic and biosimilar manufacturers) to file certain types of patent...